letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...6869707172737475767778...100101»
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal:  Palbociclib combinations as new therapeutic strategies in the treatment of HR+/HER2- advanced breast cancer (Pubmed Central) -  Oct 4, 2019   
    Until recently, the only endocrine agents used to treat HR+/HER2- advanced breast cancers were tamoxifen, aromatase inhibitors and fulvestrant, although a substantial proportion of patients relapse on these standard therapies...High level evidence supports the use of palbociclib plus letrozole in the treatment of endocrine sensitive breast cancers, or palbociclib plus fulvestrant in tumors that develop acquired resistance to endocrine therapy...The new combination regimens with palbociclib represent an important addition to the therapeutic armamentarium in locally advanced and metastatic ER+/HER2- breast cancer. The article reviews the current role of palbociclib in combination with endocrine therapy in the therapy of HR+/HER2- advanced breast cancer.
  • ||||||||||  Piqray (alpelisib) / Novartis
    Trial completion date:  BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) -  Oct 3, 2019   
    P1,  N=46, Active, not recruiting, 
    Whether the addition of tamoxifen or letrozole to standard ovarian stimulation affects the long-term follow up in terms of safety in women with breast cancer, remains to be seen.” Trial completion date: Sep 2019 --> Sep 2020
  • ||||||||||  Herceptin (trastuzumab) / Roche, paclitaxel / Generic Mfg., Reolysin (pelareorep) / Oncolytics, Andrus Reo
    A window-of-opportunity Study of pelareorep in Early Breast Cancer (AWARE-1) (Prince George's Exhibition Halls AB) -  Oct 2, 2019 - Abstract #SITC2019SITC_734;    
    Consistent with pelareorep's role in promoting adaptive anti-tumor immunity, a randomized phase 2 study in metastatic breast cancer demonstrated a statistically significant improvement in overall survival when pelareorep was combined with paclitaxel [2]...Cohort 2: HR+/HER2-neg (10 patients): pelareorep + letrozole + atezolizumab...Cohort 4: HER2+/HR+ (6 patients): pelareorep + trastuzumab + atezolizumab... N/A.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Keytruda (pembrolizumab) / Merck (MSD)
    Circulating Immune Cell Biomarkers Predict Response to Immune Checkpoint Inhibitor Therapy in Metastatic Breast Cancer (Prince George's Exhibition Halls AB) -  Oct 2, 2019 - Abstract #SITC2019SITC_733;    
    P2
    Temporal changes in T cell trafficking molecules and shifts in myeloid cell composition over the course of therapy indicate potential changes in T cell priming and regulation. Further analysis is currently ongoing to understand correlates of systemic immune changes and changes in the tumor microenvironment.
  • ||||||||||  letrozole / generics
    Journal:  17 beta- estradiol synthesis modulates cerebellar dependent motor memory formation in adult male rats. (Pubmed Central) -  Sep 26, 2019   
    To answer this question, we investigated the acute effect of blocking E2 synthesis on gain increases and decreases in VOR adaptation using an oral dose (2.5 mg/kg) of the aromatase inhibitor Letrozole in peri-pubertal and post-pubertal male rats...Thus, in adult male rats neurosteroid E2 effectively modulates VOR adaptation in both of the periods studied. These findings imply that the adult cerebellum uses E2 synthesis for modulating motor memory formation and suggest that low and extremely localized E2 production may play a role in adaptive phenomena.
  • ||||||||||  Cetrotide (cetrorelix) / EMD Serono
    Preclinical, Journal:  Evaluation of ovarian and metabolic effects of GnRH modulators in two rat models of PCOS. (Pubmed Central) -  Sep 26, 2019   
    Only testosterone level, total cholesterol level and follicular development were improved. Therefore, it was concluded that both leuprolide and cetrorelix showed improvement in follicular development which could be helpful for improving fertility in PCOS.
  • ||||||||||  letrozole / Generic mfg.
    Accuracy of split dynamic magnetic resonance imaging in locally advanced breast cancer during neoadjuvant aromatase inhibitor therapy (Hall 1) -  Sep 25, 2019 - Abstract #SABCS2019SABCS_1836;    
    This method has an advantage over the current dynamic MRI, as it provides extensive information about both structural and functional assessment of the tumor through quantitative evaluation of both T1- and T2 *- weighted characteristics.Trial Design: NEO-LET-EXE is a neoadjuvant, randomized, open-label, intra-patient cross-over trial.Eligibility criteria: Postmenopausal patients diagnosed with estrogen receptor (ER) positive (?10%) breast cancer and HER-2 negative LABC not suitable for neoadjuvant chemotherapy are eligible for the study.Specific aims: A 1.5T scanner is used to obtain and investigate the clinical utility and diagnostic accuracy of T1_T2 multi-echo EPI and dynamic THRIVE sequences during a single injection of contrast agent at baseline and following AI therapy with either letrozole or exemestane for at least two months followed by the alternative drug for another two months.The study clarifies the feasibility of split dynamic MRI method as a tool for predict treatment response, analyse biological behaviour and tumor aggressiveness.In addition, our findings will allow quantitative comparisons of the intra-tumor effects of aromatase inhibitors with clinical breast evaluations for prediction of postoperative pathologic complete response.Statistical Quantitative analysis will be performed with pharmacokinetic modelling on T1-weighted images and estimation of maximum peak change in R2* images using receiver operating characteristic (ROC) analysis...Accrual is planned to be completed within the next 2 years. Our early experience with the applied technology will be presented and discussed.
  • ||||||||||  Clonal heterogeneity and tumor evolution inform treatment resistance in a patient with HER2+ breast cancer (Hall 1) -  Sep 25, 2019 - Abstract #SABCS2019SABCS_1746;    
    At the time of appearance of this clone, Letrozole was added to the treatment and a clone with an ESR1 p.G442R mutation appeared and dominated the tumor population, suggesting that this mutation provides resistance to the aromatase inhibitor. When treatment was switched to Fulvestrant and Palbociclib, a potentially dormant clone with ER+ and HER2+ features re-appeared in the tumor.Evolutionary analysis of this patient's tumor specimens underscores the importance of multiple therapies directed at all tumor vulnerabilities present, since targeting a single driver feature of the tumor will result in selection of other resistant subclones.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Avastin (bevacizumab) / Roche
    Real-world evidence of efficacy and activity of palbociclib plus endocrine therapy and post-progression treatments in HR+/HER2- metastatic breast cancer patients: The PALPract study (Hall 1) -  Sep 25, 2019 - Abstract #SABCS2019SABCS_1709;    
    Background Several randomized clinical trials clearly demonstrated that adding palbociclib (P) to endocrine therapies (ET), such as letrozole (LT) or fulvestrant (FLV), significantly improves outcome both in first-line/endocrine sensitive and second-line/endocrine resistant hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2) metastatic breast cancer (MBC) patients (pts).The aims of the present study were to assess efficacy, activity and toxicity of P combined with either LT or FLV in a real world setting, and to study the efficacy and activity of treatments administered after progression to P + ET.Methods Records of 245 consecutive HR+/HER2- MBC patients from 14 Italian cancer centers were reviewed in this observational study...Of them, 38 (76%) received chemotherapy (capecitabine, eribulin, nab-paclitaxel, paclitaxel+bevacizumab, vinoreline) and 12 (24%) ET...Main non-hematological AEs were fatigue and gastrointestinal symptoms (diarrhea and stypsis).Conclusions Our findings confirm the efficacy and safety of P+ET as first/second-line treatment for HR+/HER2- MBC pts, even in a non-selected, real world population. Since data regarding the efficacy and activity of post-progression therapies were not mature at the time of the current analysis, they will be subsequently presented.
  • ||||||||||  letrozole / Generic mfg.
    Estrogen-depletion therapies prevent and delay progression of brain metastasis (Hall 1) -  Sep 25, 2019 - Abstract #SABCS2019SABCS_1588;    
    Pfizer (NCT00721409, NCT01740427, NCT01942135) These studies have important clinical implications as they provide pre-clinical evidence that ovarian suppression in combination with AIs can prevent and delay progression of established brain metastasis in younger women with TNBC.
  • ||||||||||  Gut microbiome profiling of patients with metastatic breast cancer undergoing immune checkpoint inhibitor therapy (Hall 1) -  Sep 25, 2019 - Abstract #SABCS2019SABCS_1550;    
    P2
    Most patients who progressed on ICI had dysbiotic gut microbiomes present at baseline and later time points, such as a high relative abundance of Prevotella (implicated in inflammatory processes); this often resolved during therapy. Our observations provide promise for future use of the gut microbiome as a predictor of response to immunotherapy for BC and the potential for modulating the gut microbiome to improve responses in patients with dysbiosis.